A decision was taken on June 3, 2015 at the Annual General Meeting for AroCell AB (publ) that a nomination committee should be appointed and should consist of three members, comprised of the three largest shareholders on September 30, 2015, and the Chairman of the Board.
The nomination committee has been appointed accordingly, based on shareholdings on September 30, 2015:
Bernhard Tribukait, representing his own shareholdings
Arne Ferstad, representing his own and related shareholdings
Staffan Eriksson, representing his own and related shareholdings
Erik Walldén, Chairman of the Board
Arne Ferstad has been appointed as chairman of the nomination committee.
The nomination committee collectively represents approximately 11.7 percent of shareholder votes in AroCell AB (publ).
The Annual General Meeting will be held in Uppsala, Sweden on May 18, 2016.
Shareholders who wish to contact the nominating committee may do so by email to firstname.lastname@example.org or by letter to:
AroCell AB (publ)
Virdings allé 32B
754 50 UPPSALA
Board of Directors
For more information please contact:
About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB is listed at AktieTorget (AROC) and has about 2 300 shareholders.